Hagler Mark Arnold
SEC CIK 2126029 · EDGAR
BoughtSold
Companies
| Ticker | Company | Title | Holding | Bought | Sold | Trades | First | Last |
|---|---|---|---|---|---|---|---|---|
| NBP | NovaBridge Biosciences | See Remarks | 230.0K | $577.3K | — | 1 | 2026-04-24 | 2026-04-24 |
Most active insiders at NBP, 12 months
| # | Insider | Title | Bought | Sold |
|---|---|---|---|---|
| 1 | Hagler Mark Arnold | See Remarks | $577.3K | — |
| 2 | Cao Sean Wuxiong | See Remarks, Dir | — | $122.5K |
| 3 | Xu Cong Claire | SVP, Clinical Development | — | $20.4K |
| 4 | Dennis Phillip Andrew | Chief Medical Off | — | $11.4K |
| 5 | Lenz Robert A. | Dir | — | — |
Transactions 1
| X | Filed | Traded | Ticker | Company | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-04-28 16:05 | 2026-04-24 | NBP | NovaBridge Biosciences | Hagler Mark Arnold | See Remarks | P - Purchase | $2.51 | +230.0K | 230.0K | New | +$577.3K |
Purchase Sale Sale after option exercise All abbreviations